Skip to search formSkip to main contentSkip to account menu

OGX-011

Known as: ISIS 112989 
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Thionucleotidesclusterin antisense oligonucleotide

Narrower (1)

custirsen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Small heat shock proteins in cancer therapy and prognosis.
Review
2011
Review
2011
New therapies for castration-resistant prostate cancer: efficacy and safety.
Highly Cited
2011
Highly Cited
2011
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after…
Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This… 
Highly Cited
2010
Highly Cited
2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
PURPOSE To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel… 
Highly Cited
2008
Highly Cited
2008
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
Purpose: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… 
Highly Cited
2008
Highly Cited
2008
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
To characterize changes in secretory clusterin (sCLU) expression in prostate cancer cells after treatment with docetaxel and to… 
Review
2008
Review
2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small… 
Highly Cited
2007
Highly Cited
2007
Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
The pharmacokinetics of a 2′-O-(2-methoxyethyl)-modified oligonucleotide, ISIS 301012 [targeting human apolipoprotein B-100 (apoB… 
Highly Cited
2005
Highly Cited
2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
BACKGROUND Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… 
Review
2005
Review
2005
Antisense therapy for cancer
Improved understanding of the molecular mechanisms that mediate cancer progression and therapeutic resistance has identified many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License